Wegovy Tablets Side Effects: Complete Guide

Wegovy Tablets Side Effects: Complete Guide

As of May 8, 2026, Wegovy is no longer just an injection-only conversation. Novo Nordisk's current Wegovy materials and the U.S. FDA tablet label describe Wegovy tablets as a once-daily oral semaglutide option.

That means a side-effects guide for Wegovy tablets should talk about a real, approved product rather than a hypothetical future formulation. Consult your healthcare provider before starting any medication.

What are Wegovy tablets?

Wegovy tablets contain semaglutide, a GLP-1 receptor agonist. Like injectable Wegovy, they are used in weight-management discussions because semaglutide can reduce appetite, increase fullness, and slow gastric emptying.

The tablet format changes the day-to-day routine, but it does not remove the need to watch for semaglutide-related side effects.

Common side effects of Wegovy tablets

The most common side effects are still mainly gastrointestinal. These often show up most strongly when starting treatment or moving up in dose.

Nausea

Nausea is one of the most common semaglutide side effects. It may feel like mild queasiness or more persistent discomfort.

Vomiting

Some people also experience vomiting, especially during early dose escalation.

Diarrhoea

Loose stools or more frequent bowel movements can happen as your body adjusts.

Constipation

Other people notice the opposite pattern, with slower bowel movements or constipation.

Abdominal pain, bloating, or gas

Because semaglutide slows stomach emptying, some users report abdominal discomfort, bloating, burping, or a heavy/full feeling after meals.

Other side effects that can happen

Beyond the digestive system, some patients report:

• headache
• tiredness or fatigue
• dizziness
• reduced appetite beyond what they expected

Why side effects happen

Many of these effects are linked to how semaglutide works. It affects appetite signaling and slows the rate at which food leaves the stomach. That mechanism can be helpful for weight management, but it also explains why digestive side effects are so common.

Serious but less common side effects

Like other semaglutide products, Wegovy tablets can also raise concern for more serious problems that need prompt medical attention.

Pancreatitis

Seek urgent medical advice if you develop severe stomach pain that does not go away, especially if it spreads to your back.

Gallbladder problems

Warning signs can include upper-abdominal pain, fever, nausea, vomiting, or yellowing of the skin or eyes.

Kidney problems from dehydration

Persistent vomiting or diarrhoea can lead to dehydration, which may worsen kidney function.

Serious allergic reactions

Get urgent help if you develop swelling of the face, lips, tongue, or throat, trouble breathing, or a severe rash.

Thyroid tumor warning

Semaglutide products carry a boxed warning based on rodent studies about possible thyroid C-cell tumors. Patients with a personal or family history of medullary thyroid carcinoma or MEN 2 should review this carefully with their clinician.

Tips to discuss with your clinician

Many people do better when they:

• eat smaller meals
• avoid large, greasy, or very rich meals when nausea is active
• stay hydrated
• report persistent vomiting, constipation, or abdominal pain early
• avoid making dose changes on their own

When to contact your clinician

Reach out if:

• side effects are severe or do not settle
• you cannot keep fluids down
• you develop severe abdominal pain
• you notice yellowing of the skin or eyes
• you are thinking about stopping treatment because of side effects

Bottom line

Wegovy tablets are now a real oral semaglutide product, so their side-effect guide should be grounded in current tablet status. The most common issues are still gastrointestinal—especially nausea, vomiting, diarrhoea, constipation, and abdominal discomfort—but serious warning symptoms still matter and should be reviewed with a clinician.

That conversation is the safest way to weigh whether the tablet form fits your treatment goals and tolerance. Consult your healthcare provider before starting any medication.

Sources

• https://www.wegovy.com/
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/218316Orig1s000lbl.pdf
• https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-management-first-2014
• https://medlineplus.gov/druginfo/meds/a619057.html
• https://www.nejm.org/doi/full/10.1056/NEJMoa2302302